Form D · Pharmaceuticals

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Cupertino, CA · CIK 0001742927

Offering snapshot reported Sep 19, 2022 · SEC filing

Reported sold
$0
Indefinite offering
Investors reported
3
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 8, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 19, 2022Initial$0No comparison3SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0 (estimated)
Finders' fees
$0 (estimated)
Form D file number
021-459214
Value of warrants indeterminable as they were issued in connection with a concurrent registered direct offering of common stock.
See Item 13. Fees payable to placement agent solely for the issuance of the warrants indeterminable.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
A.G.P./Alliance Global Partners8361

Source: Form D, filed Sep 19, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Laxminarayan Bhat Director, Executive
Les Funtleyder Director
Richard Margolin Director
Purav Patel Director
Narayan Prabhu Executive
Parag Saxena Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
19925 Stevens Creek Blvd. Suite 100
Cupertino, CA, 95014